Kupando has dosed the first patient in its phase 1 study evaluating KUP101 in advanced solid tumours, marking the company’s transition into a clinical-stage biopharmaceutical organisation. The trial focuses initially on advanced skin tumors.
The milestone reflects Kupando’s evolution from a research-focused group into a clinical developer, moving its dual TLR 4/7 agonist from laboratory work into human testing.
Dr Johanna Holldack, Founder and CEO of Kupando, said: “Dosing our first patient is a defining inflection point in Kupando’s history.
By leveraging the power of innate immune stimulation and the induction of trained immunity, KUP101 represents a fundamentally different way of approaching hard-to-treat cancers.”
She added: “Moving into the clinic is a testament to the dedication of our team, our clinical investigators in Germany, and the strong backing of our investor syndicate.”
Following the first administration, the safety committee has reviewed initial dosing and cleared continued enrolment across activated sites. The study is being conducted at leading oncology centres in Germany.
KUP101 is a first-in-class dual TLR 4 and 7 agonist designed to stimulate the innate immune system and activate immunocompetent cells in the tumour microenvironment.
Because it works through immune activation rather than mutation targeting, it is intended as a tissue-agnostic therapy capable of producing broader and more durable responses.
Preclinical studies have shown synergistic and additive effects when KUP101 is combined with checkpoint inhibitors, offering potential benefit for patients who do not respond to or develop resistance to existing immunotherapies.
Kupando is also advancing a preclinical pipeline in infectious diseases, targeting antimicrobial resistance through pathogen-agnostic host-directed approaches.
